Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $102,047.40 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 2,940 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the sale, the insider owned 80,277 shares of the company’s stock, valued at $2,786,414.67. This represents a 3.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Stock Down 3.8%

NASDAQ:AGIO opened at $33.77 on Thursday. The company has a fifty day moving average of $29.24 and a 200-day moving average of $32.11. The firm has a market capitalization of $1.98 billion, a P/E ratio of -4.75 and a beta of 0.79. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. Marshall Wace LLP lifted its stake in Agios Pharmaceuticals by 31.4% in the second quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock worth $22,772,000 after acquiring an additional 163,796 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Agios Pharmaceuticals in the third quarter worth $2,696,000. HighVista Strategies LLC lifted its stake in Agios Pharmaceuticals by 178.5% in the third quarter. HighVista Strategies LLC now owns 195,298 shares of the biopharmaceutical company’s stock worth $7,839,000 after acquiring an additional 125,171 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in Agios Pharmaceuticals by 19.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock worth $42,565,000 after acquiring an additional 209,900 shares during the period. Finally, Boothbay Fund Management LLC lifted its stake in Agios Pharmaceuticals by 71.1% in the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock worth $14,868,000 after acquiring an additional 185,798 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AGIO shares. JPMorgan Chase & Co. lifted their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Monday. Truist Financial lifted their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. The Goldman Sachs Group lifted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Finally, Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $42.67.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.